ES2602971T3 - Composición de anticuerpo modificado - Google Patents

Composición de anticuerpo modificado Download PDF

Info

Publication number
ES2602971T3
ES2602971T3 ES11750612.1T ES11750612T ES2602971T3 ES 2602971 T3 ES2602971 T3 ES 2602971T3 ES 11750612 T ES11750612 T ES 11750612T ES 2602971 T3 ES2602971 T3 ES 2602971T3
Authority
ES
Spain
Prior art keywords
amino acid
ser
asn
thr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11750612.1T
Other languages
English (en)
Inventor
Rinpei Niwa
Mami Tsuchiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2602971T3 publication Critical patent/ES2602971T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Image Processing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composición de variante de anticuerpo y fragmento de la composición de variante de anticuerpo, que comprende los residuos de aminoácidos de una secuencia Asn-X-Ser/Thr (X representa un residuo de aminoácido diferente de Pro) en una región Fc de un anticuerpo IgG humano, realizándose en dicha secuencia Asn-X-Ser/Thr por lo menos una sustitución de aminoácido seleccionada de entre una sustitución de aminoácido de Asn por otro residuo de aminoácido, una sustitución de aminoácido de X por Pro y una sustitución de aminoácido de Ser/Thr por otro residuo de aminoácido, en la/el que la secuencia Asn-X-Ser/Thr (X es un residuo de aminoácido diferente de Pro) son los residuos de aminoácidos en las posiciones 392 a 394 según el índice EU, y en la/el que la región Fc de un anticuerpo IgG humano comprende la secuencia de aminoácidos de SEC ID nº 1.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54

Claims (1)

  1. imagen1
ES11750612.1T 2010-03-02 2011-02-28 Composición de anticuerpo modificado Active ES2602971T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963110P 2010-03-02 2010-03-02
US309631P 2010-03-02
PCT/JP2011/054549 WO2011108502A1 (ja) 2010-03-02 2011-02-28 改変抗体組成物

Publications (1)

Publication Number Publication Date
ES2602971T3 true ES2602971T3 (es) 2017-02-23

Family

ID=44542154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11750612.1T Active ES2602971T3 (es) 2010-03-02 2011-02-28 Composición de anticuerpo modificado

Country Status (9)

Country Link
US (2) US9556279B2 (es)
EP (1) EP2543727B1 (es)
JP (1) JP5820800B2 (es)
KR (1) KR101913440B1 (es)
CN (1) CN102782131B (es)
AU (1) AU2011222012C1 (es)
CA (1) CA2791652C (es)
ES (1) ES2602971T3 (es)
WO (1) WO2011108502A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
US20150337037A1 (en) * 2012-06-05 2015-11-26 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
US20140212409A1 (en) * 2012-08-13 2014-07-31 Kyowa Hakko Kirin Co., Ltd. METHOD FOR INCREASING DEPOSITION OF COMPLEMENT C3b ON BACTERIAL SURFACE AND PHAGOCYTOSIS BY PHAGOCYTE AND A THERAPEUTIC METHOD AND A THERAPEUTIC AGENT FOR BACTERIAL INFECTIONS
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
ES2881306T3 (es) * 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
US10745463B2 (en) 2013-11-18 2020-08-18 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective Fc receptor binding
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
SG11202101099PA (en) * 2018-08-29 2021-03-30 United Biopharma Inc Afucosylated antibodies and manufacture thereof
US20210380684A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Antibody composition
CN109781986B (zh) * 2019-03-11 2022-03-25 复旦大学附属妇产科医院 一种磁微粒化学发光免疫检测CA125表面Tn抗原的试剂盒及其制备方法
AU2021249888A1 (en) 2020-04-01 2022-10-27 Kyowa Kirin Co., Ltd. Antibody composition
AU2021282817B2 (en) * 2020-06-01 2025-07-03 Mustbio Co., Ltd. Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
ATE255162T1 (de) 1983-01-13 2003-12-15 Max Planck Gesellschaft Transgene dicotyledone pflanzenzellen und pflanzen
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
ATE204017T1 (de) 1984-05-11 2001-08-15 Syngenta Participations Ag Transformation von pflanzenerbgut
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP3756946B2 (ja) 1993-03-29 2006-03-22 協和醗酵工業株式会社 α１，３−フコシルトランスフェラーゼ
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
JP4550947B2 (ja) 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7592005B2 (en) 2000-12-28 2009-09-22 Kirin Beer Kabushiki Kaisha Monoclonal antibody
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2478973A1 (en) 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004280066A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP5367982B2 (ja) * 2004-04-16 2013-12-11 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
SV2007002227A (es) 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US8716451B2 (en) * 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007011041A1 (ja) 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007142277A1 (ja) 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
EP2130552B1 (en) 2007-02-27 2016-06-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009154995A2 (en) 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US8268592B2 (en) 2008-07-17 2012-09-18 Kyowa Hakko Kirin Co., Ltd Anti-system ASC amino acid transporter 2 (ASCT2) antibody
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体

Also Published As

Publication number Publication date
AU2011222012A1 (en) 2012-09-27
US20170166650A1 (en) 2017-06-15
CA2791652C (en) 2018-06-12
WO2011108502A1 (ja) 2011-09-09
CA2791652A1 (en) 2011-09-09
KR101913440B1 (ko) 2018-10-30
JPWO2011108502A1 (ja) 2013-06-27
AU2011222012B2 (en) 2014-07-17
CN102782131A (zh) 2012-11-14
EP2543727B1 (en) 2016-08-31
KR20130002987A (ko) 2013-01-08
US20120010387A1 (en) 2012-01-12
EP2543727A1 (en) 2013-01-09
AU2011222012C1 (en) 2015-02-26
CN102782131B (zh) 2015-08-05
EP2543727A4 (en) 2013-11-20
US9556279B2 (en) 2017-01-31
US10040861B2 (en) 2018-08-07
JP5820800B2 (ja) 2015-11-24

Similar Documents

Publication Publication Date Title
ES2602971T3 (es) Composición de anticuerpo modificado
ES2600879T3 (es) Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
CL2020000498A1 (es) Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920)
MX2020013068A (es) Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
CO6210757A2 (es) Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo
PE20210049A1 (es) Composiciones agonistas de gip/glp1
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
AR114565A1 (es) Proteínas de fusión fc il-22 y métodos de uso
ES2627330T3 (es) Uso de JAZ5a para mejorar la resistencia a la sequía en una planta
UA110383C2 (en) Deicing composition
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
PE20140844A1 (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
MX2013014857A (es) Señalizacion de imagenes de referencia.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
AR092981A1 (es) Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
JP2013530929A5 (es)
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX2019005137A (es) Vacuna contra parvovirus porcino.
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
PE20131363A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos